HERTINIB(Lapatinib)
Therapeutic class: Kinase inhibitor
- capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
250 mg Tablets
250 mg:- A bottle of 30 and 60 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
